Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: A small-scale clinical study

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Shiochi, Hideki ^a   Ohkura, Tsuyoshi ^a   Fujioka, Yohei ^a   Sumi, Keisuke ^a   Yamamoto, Naoya ^a   Nakanishi, Risa ^a   Matsuzawa, Kazuhiko ^a   Izawa, Schoichiro ^a   Ohkura, Hiroko ^a   Inoue, Kazuoki ^a   Ueta, Etsuko ^a   Kato, Masahiko ^a   Taniguchi, Shin Ichi ^a   Yamamoto, Kazuhiro ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Bezafibrate; Glucose clamp; Insulin resistance; Japanese patients; Meal tolerance test; Type 2 diabetes mellitus

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; DYSLIPIDEMIA; ENDOCRINE FUNCTION TEST; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; GLUCOSE INTOLERANCE; HUMAN; IMMUNOREACTIVITY; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; MEAL TOLERANCE TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 84989208865     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-113     Document Type: Article

References (43)

1. DeFronzo RA: Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988, 37:667-687.
2. The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease the bezafibrate infarction prevention (BIP) study. Circulation 2000, 102:21-27.
3. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005, 165:1154-1160.
4. Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, Leor J, Boyko V, Schwammenthal E, Behar S: Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005, 26:2032-2038.
5. Flory JH, Strom BL, Ellenberg S, Hennessy S, Szapary PO: Antidiabetic action of bezafibrate in a large observational database. Diabetes Care 2009, 32(4):547-551.
6. Teramoto T, Shirai K, Daida H, Yamada N: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: The J-BENEFIT study. Cardiovasc Diabetol 2012, 11:29-38.
7. DeFronzo RA, Ferrannini E, Hendler R, Wahren J, Felig P: Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. Proc Natl Acad Sci U S A 1978, 75:5173-5177.
8. DeFronzo RA, Tobin JD, Antres R: Glucose clamp technique: A method for quantifying insulin secresion and resistence. Am J Physiol 1979, 237:214-223.
9. Karhapaa P, Uusitupa M, Voutilainen E, Laakso M: Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia. Clin Pharmacol Ther 1992, 52:620-626.
10. Riccardi G, Genovese S, Saldalamacchia G, Patti L, Marotta G, Postiglione A, Rivellese A, Capaldo B, Mancini M: Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes. Antherosclerosis 1989, 75:175-181.
11. Unsitupa MI, Niskanen LK, Siitonen O, Voutilainen E E, Pyörälä K: 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 1990, 82:27-36.
12. Khan HA, Sobki SH, Khan SA: Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med 2007, 7:24-29.
13. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, Maerker E, Matthaei S, Schick F, Claussen CD, Haring HU: Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999, 48:1113-1119.
14. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
15. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishiro Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H: Committee on the standardization of diabetes mellitus-related laboratory testing of Japan diabetes society, "International clinical harmonization of glycated hemoglobin in Japan: from Japan diabetes society to national glycohemoglobin standardization program values. J Diabetes Invest 2012, 3:39-40.
16. Ohkura T, Shiochi H, Fujioka Y, Sumi K, Yamamoto N, Matsuzawa K, Izawa S, Kinoshita H, Ohkura H, Kato M, Taniguchi S, Yamamoto K: 20/(fasting C-peptide x fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: A preliminary report. Cardiovasc Diabetol 2013, 12:21.
17. Sumi K, Ohkura T, Yamamoto N, Fujioka Y, Matsuzawa K, Izawa S, Shiochi H, Kinoshita H, Ohkura H, Kato M, Yamamoto K, Taniguchi S: Long-Term miglitol administration suppresses postprandial glucose-dependent insulinotropic polypeptide secretion. Diabetol Int 2013, 4:190-196.
18. Ohkura T, Inoue K, Fujioka Y, Nakanishi R, Shiochi H, Sumi K, Yamamoto N, Matsuzawa K, Izawa S, Ohkura H, Kato M, Yamamoto K, Taniguchi SI: The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: A small-scale clinical study. BMC Res Notes 2013, 6:453.
19. Kawamori R, Matsushita J, Mochizuki K, Niwa M, Arisaka T, Ikeda M, Kubota M, Wada T, Ikebuchi M, Tohdo R, Yamasaki Y: Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1998, 41:35-43.
20. Tamura Y, Tanaka Y, Sato F, Choi JB, Watada H, Niwa M, Kinoshita J, Ooka A, Kumashiro N, Igarashi Y, Kyogoku S, Maehara T, Kawasumi M, Hirose T, Kawamori R: Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005, 90:3191-3196.
21. Yoshino G, Tominaga M, Hirano T, Shiba T, Kashiwagi A, Tanaka A, Tada N, Onuma T, Egusa G, Kuwashima M, Sanke T, Oikawa S, Honda K, Tachikawa T: The test meal A: A pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. Journal of the Japan Diabetes Society 2006, 49:361-371.
22. Turner RC, Holman RR, Matthews D, Hockaday TDR, Peto J: Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism 1979, 28:1086-1096.
23. Tenenbaum H, Behar S, Boyko V, Adler Y, Fisman EZ, Tanne D, Lapidot M, Schwammenthal E, Feinberg M, Matas Z, Motro M, Tenenbaum A: Long-Term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 2007, 194:265-271.
24. Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S: Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006, 166:737-741.
25. Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347:645-650.
26. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43:527-550.
27. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Different expression of peroxisome proliferator-Activated receptors (PPARs): Tissue distribution of PPAR-Alpha,-beta, and-gamma in the adult rat. Endocrinology 1996, 137:354-366.
28. Anboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville P, Vidal H: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-Activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997, 46:1319-1327.
29. Barish GD, Narkar VA, Evans RM: PPARδ: A dagger in the heart of the metabolic syndrome. J Clin Invest 2006, 116:590-597.
30. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators: Effects of long-Term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
31. Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Matsunaga T, Hayashi K, Awata T, Komoda T, Katayama S: Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun 2002, 290:131-139.
32. Fernandes-Santos C, Carnerio RE, Mendonca LS, Aguila MB, Mandarin-de-Lacerda CA: Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet. Nutrition 2009, 25:818-827.
33. Yamada K, Tsunoda K, Kawai K, Ikeda T, Taguchi K, Kajita K, Morita H, Ishizuka T: Mitochondria toxicity on antihyperlipidemic agents bezafibrate and fenofibrate. Diabetol Int 2013, 4:126-131.
34. Andres R, Cadar G, Zierler K: The quantitatively minor role of carbohydrate in oxidative metabolism by skeletal muscle in intact man in the basal state. J Clin Invest 1956, 35:671-682.
35. Matsui H, Okumura K, Kawakami K, Hibino M, Ito T: Improved insulin sensitivity by bezafibrate in rats: relationship to fatty acid composition of skeletal-muscle triglycerides. Diabetes 1997, 46:348-353.
36. Sasaki Y, Shimada T, Iizuka S, Suzuki W, Makihara H, Teraoka R, Tsuneyama K, Hokao R, Aburada M: Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome. Eur J Pharmacol 2011, 662:1-8.
37. Cariou B, Hanf R, Lambert-Porcheron S, Zair V, Noel B, Flet L, Vidal H, Staels B, Laville M: Dual peroxisome proliferator-Activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 2013, 36:2923-2930.
38. Basu R, Di Camillo B, Toffolo G, Basu A, Shah P, Vella A, Rizza R, Cobelli C: Use of a novel triple tracer approach to assess postprandial glucose metabolism. Am J Physiol Endocrinol Metab 2003, 284:E55-E69.
39. Dalla Man C, Toffolo G, Basu R, Rizza RA, Cobelli C: Use of labeled oral minimal model to measure hepatic insulin sensitivity. Am J Physiol Endocrinol Metab 2008, 295:E1152-E1159.
40. Tamura Y, Watada H, Sato F, Kumashiro N, Sakurai Y, Hirose T, Tanaka Y, Kawamori R: Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects. Diabetes Obes Metab 2008, 10:733-738.
41. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM: Peroxisome-proliferator-Activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159-170.
42. Tenenbaum A, Fisman EZ: Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetee prevention? Cardiovasc Diabetol 2012, 11:140.
43. Teramoto T, Abe K, Taneyama T: Safety and efficacy of long-Term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study. Cardiovasc Diabetol 2013, 12:163.